P
Pierfranco Conte
Researcher at University of Padua
Publications - 699
Citations - 29374
Pierfranco Conte is an academic researcher from University of Padua. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 72, co-authored 665 publications receiving 24001 citations. Previous affiliations of Pierfranco Conte include University of Turin & University of Modena and Reggio Emilia.
Papers
More filters
Journal ArticleDOI
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
H. von der Maase,S.W. Hansen,J.T. Roberts,Luigi Dogliotti,T. Oliver,M.J. Moore,István Bodrogi,P. Albers,A. Knuth,C.M. Lippert,P. Kerbrat,P. Sanchez Rovira,P. Wersall,S.P. Cleall,D.F. Roychowdhury,I. Tomlin,C.M. Visseren-Grul,Pierfranco Conte +17 more
TL;DR: GC provides a similar survival advantage to MVAC with a better safety profile and tolerability, and this better-risk benefit ratio should change the standard of care for patients with locally advanced and metastatic TCC from MVAC to GC.
Journal ArticleDOI
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark E. Robson,Seock-Ah Im,Elżbieta Senkus,Binghe Xu,Susan M. Domchek,Norikazu Masuda,Suzette Delaloge,Wei Li,Nadine Tung,Anne Armstrong,Wenting Wu,C. Goessl,Sarah Runswick,Pierfranco Conte +13 more
TL;DR: Among patients with HER2‐negative metastatic breast cancer and a germline BRCA mutation, Olaparib monotherapy provided a significant benefit over standard therapy; median progression‐free survival was 2.8 months longer and the risk of disease progression or death was 42% lower with olaparIB monotherapy than with standard therapy.
Journal ArticleDOI
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
M Marty,Francesco Cognetti,Dominique Maraninchi,Raymond Snyder,Louis Mauriac,Michèle Tubiana-Hulin,Stephen Chan,David Grimes,Antonio Antón,Anna Lluch,John Kennedy,Kenneth J. O'Byrne,Pierfranco Conte,Michael D. Green,Carol Ward,Karen Mayne,Jean-Marc Extra +16 more
TL;DR: Tastuzumab combined with docetaxel is superior to docetAXel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity.
Journal ArticleDOI
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi,Salomon M. Stemmer,Howard A. Burris,Yoon Sim Yap,Gabe S. Sonke,Shani Paluch-Shimon,Mario Campone,Kimberly L. Blackwell,Fabrice Andre,Eric P. Winer,Wolfgang Janni,Sunil Verma,Pierfranco Conte,Carlos L. Arteaga,David Cameron,Katarína Petráková,Lowell L. Hart,Cristian Villanueva,A. Chan,Erik Jakobsen,Arnd Nusch,Olga Burdaeva,Eva-Maria Grischke,Emilio Alba,Erik Wist,Norbert Marschner,Anne Favret,Denise A. Yardley,Thomas Bachelot,Ling-Ming Tseng,Sibel Blau,Fengjuan Xuan,Farida Souami,Michelle Miller,C. Germa,Samit Hirawat,Joyce O'Shaughnessy +36 more
TL;DR: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.
Journal ArticleDOI
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
José Baselga,Karen A. Gelmon,Shailendra Verma,Andrew M Wardley,Pierfranco Conte,David Miles,Giulia Bianchi,Javier Cortes,V. McNally,Graham Ross,Pierre Fumoleau,Luca Gianni +11 more
TL;DR: The combination of pertuzumsumab and trastuzumab is active and well tolerated in patients with metastatic HER2-positive breast cancer who had experienced progression during prior trastzumab therapy.